Bexagliflozin
Brenzavvy (bexagliflozin) is a prescription oral tablet used to manage type 2 diabetes by lowering blood sugar levels. As an SGLT2 inhibitor, it helps the kidneys remove excess glucose through urine. Available in 20 mg strength, manufactured by TheracosBio, LLC. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Brenzavvy (bexagliflozin) is a prescription oral tablet used to manage type 2 diabetes by lowering blood sugar levels. As an SGLT2 inhibitor, it helps the kidneys remove excess glucose through urine. Available in 20 mg strength, manufactured by TheracosBio, LLC. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Bexagliflozin",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Bexagliflozin — ANDA 214373 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214373"
}
]
|
| identifier | ANDA214373 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-safety",
"health-care",
"pharmaceuticals",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Bexagliflozin |
